Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.

× No keyword cloud information.

28 in total

1. Chloroquine and QTc interval.

Authors: J A Silva; M B Silva; T L Skare
Journal: Clin Exp Rheumatol Date: 2007 Sep-Oct Impact factor: 4.473

2. Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.

Authors: Ahmet Emre Eskazan; Teoman Soysal; Seniz Ongoren; Emine Gulturk; Burhan Ferhanoglu; Yildiz Aydin
Journal: Haematologica Date: 2011-03 Impact factor: 9.941

3. Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities-Which TKI is the safest?

Authors: Ahmet Emre Eşkazan
Journal: Br J Clin Pharmacol Date: 2019-08-22 Impact factor: 4.335

4. Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?

Authors: Ahmet Emre Eskazan; Deniz Ozmen
Journal: Expert Rev Hematol Date: 2017-06-13 Impact factor: 2.929

5. COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis.

Authors: Aakash Desai; Sonali Sachdeva; Tarang Parekh; Rupak Desai
Journal: JCO Glob Oncol Date: 2020-04

Review 6. Dasatinib-induced pulmonary arterial hypertension.

Authors: Nurgül Özgür Yurttaş; Ahmet Emre Eşkazan
Journal: Br J Clin Pharmacol Date: 2018-03-06 Impact factor: 4.335

7. Discovering drugs to treat coronavirus disease 2019 (COVID-19).

Authors: Liying Dong; Shasha Hu; Jianjun Gao
Journal: Drug Discov Ther Date: 2020

Review 8. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Authors: J L Steegmann; M Baccarani; M Breccia; L F Casado; V García-Gutiérrez; A Hochhaus; D-W Kim; T D Kim; H J Khoury; P Le Coutre; J Mayer; D Milojkovic; K Porkka; D Rea; G Rosti; S Saussele; R Hehlmann; R E Clark
Journal: Leukemia Date: 2016-04-28 Impact factor: 11.528

Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.

1. Chloroquine and QTc interval.

2. Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.

3. Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities-Which TKI is the safest?

4. Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?

5. COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis.

Review 6. Dasatinib-induced pulmonary arterial hypertension.

7. Discovering drugs to treat coronavirus disease 2019 (COVID-19).

Review 8. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

9. QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient.

10. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.

Review 1. What Do We Currently Know About Chronic Myeloid Leukemia (CML) and COVID-19?

2. COVID-19 in Chronic-Phase Chronic Myeloid Leukemia Patients: A Single-Center Survey from Turkey